Fundamental Analysis of EIGER BIOPHARMACEUTICALS INC(NASDAQ:EIGR) stock

Fundamental Rating

Overall EIGR gets a fundamental rating of 2 out of 10. We evaluated EIGR against 588 industry peers in the Biotechnology industry. EIGR has a bad profitability rating. Also its financial health evaluation is rather negative. EIGR is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

EIGR had negative earnings in the past year.

EIGR had a negative operating cash flow in the past year.

EIGR had negative earnings in each of the past 5 years.

EIGR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

EIGR has a Return On Assets of -193.08%. This is amonst the worse of the industry: EIGR underperforms 89.08% of its industry peers.

		Industry Rank	Sector Rank
ROA	-193.08%
ROE	N/A
ROIC	N/A

ROA(3y)-100.16%

ROA(5y)-82.53%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of EIGR (99.87%) is better than 99.32% of its industry peers.

The Profit Margin and Operating Margin are not available for EIGR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	99.87%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EIGR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, EIGR has less shares outstanding

EIGR has less shares outstanding than it did 5 years ago.

The debt/assets ratio for EIGR is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -24.61, we must say that EIGR is in the distress zone and has some risk of bankruptcy.

EIGR has a Altman-Z score of -24.61. This is amonst the worse of the industry: EIGR underperforms 88.40% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-24.61

ROIC/WACCN/A

WACC7.86%

2.3 Liquidity

EIGR has a Current Ratio of 0.71. This is a bad value and indicates that EIGR is not financially healthy enough and could expect problems in meeting its short term obligations.

EIGR's Current ratio of 0.71 is on the low side compared to the rest of the industry. EIGR is outperformed by 93.52% of its industry peers.

EIGR has a Quick Ratio of 0.71. This is a bad value and indicates that EIGR is not financially healthy enough and could expect problems in meeting its short term obligations.

EIGR has a Quick ratio of 0.68. This is amonst the worse of the industry: EIGR underperforms 92.83% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.71
Quick Ratio	0.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EIGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -348.44%.

EIGR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.01%.

EPS 1Y (TTM)-348.44%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-1495.35%

Revenue 1Y (TTM)17.01%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q40.85%

3.2 Future

Based on estimates for the next years, EIGR will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.90% on average per year.

Based on estimates for the next years, EIGR will show a very strong growth in Revenue. The Revenue will grow by 24.85% on average per year.

EPS Next Y68.29%

EPS Next 2Y38.81%

EPS Next 3Y25.95%

EPS Next 5Y14.9%

Revenue Next Year37.05%

Revenue Next 2Y33.22%

Revenue Next 3Y23.14%

Revenue Next 5Y24.85%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EIGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year EIGR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as EIGR's earnings are expected to grow with 25.95% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.81%

EPS Next 3Y25.95%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EIGR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EIGER BIOPHARMACEUTICALS INC

NASDAQ:EIGR (4/10/2024, 7:00:01 PM)

After market: 1.7 -0.03 (-1.45%)

1.725

-0.17 (-9.21%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.55M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-193.08%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	99.87%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.41

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.71
Quick Ratio	0.68
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-348.44%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y68.29%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)17.01%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EIGER BIOPHARMACEUTICALS INC (EIGR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens